Helicobacter Pylori First-line Treatment in Patients Allergic to Penicillin
Helicobacter Pylori Infection

About this trial
This is an interventional treatment trial for Helicobacter Pylori Infection focused on measuring Allergic, Penicillin, Helicobacter pylori, Eradication, Tetracycline
Eligibility Criteria
Inclusion Criteria:
- Patients aged 18-70 with H. pylori infection.
- Patients Allergic to Penicillin.
Exclusion Criteria:
- Patients with previous H. pylori eradication therapy.
- Patients treated with Histamine-receptor antagonist, proton pump inhibitor, bismuth and antibiotics in the previous 4 weeks.
- Patients with gastrectomy, acute gastrointestinal bleeding and advanced gastric cancer.
- Patients with known or suspected allergy to study medications.
- Currently pregnant or lactating.
- Inability to provide informed consent
Sites / Locations
- Qilu hospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
levofloxacin-tetracycline-containing quadruple group
tinidazole-tetracycline-containing quadruple group
patients in levofloxacin-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and levofloxacin 500mg po qd for 14d
patients in tinidazole-tetracycline-containing quadruple group will receive lansoprazole 30mg po bid, tetracycline 500mg po qid , bismuth subcitrate (Colloidal Bismuth Pectin) 200mg po bid, and tinidazole 500mg po tid for 14d.